Literature DB >> 25553930

Evaluation of the MeltPro TB/STR assay for rapid detection of streptomycin resistance in Mycobacterium tuberculosis.

Ting Zhang1, Siyu Hu1, Guoli Li2, Hui Li3, Xiaoli Liu4, Jianjun Niu5, Feng Wang4, Huixin Wen6, Ye Xu7, Qingge Li8.   

Abstract

Rapid and comprehensive detection of drug-resistance is essential for the control of tuberculosis, which has facilitated the development of molecular assays for the detection of drug-resistant mutations in Mycobacterium tuberculosis. We hereby assessed the analytical and clinical performance of an assay for streptomycin-resistant mutations. MeltPro TB/STR is a closed-tube, dual-color, melting curve analysis-based, real-time PCR test designed to detect 15 streptomycin-resistant mutations in rpsL 43, rpsL 88, rrs 513, rrs 514, rrs 517, and rrs 905-908 of M. tuberculosis. Analytical studies showed that the accuracy was 100%, the limit of detection was 50-500 bacilli per reaction, the reproducibility in the form of Tm variation was within 1.0 °C, and we could detect 20% STR resistance in mixed bacterial samples. The cross-platform study demonstrated that the assay could be performed on six models of real-time PCR instruments. A multicenter clinical study was conducted using 1056 clinical isolates, which were collected from three geographically different healthcare units, including 709 STR-susceptible and 347 STR-resistant isolates characterized on Löwenstein-Jensen solid medium by traditional drug susceptibility testing. The results showed that the clinical sensitivity and specificity of the MeltPro TB/STR was 88.8% and 95.8%, respectively. Sequencing analysis confirmed the accuracy of the mutation types. Among all the 8 mutation types detected, rpsL K43R (AAG → AGG), rpsL K88R (AAG → AGG) and rrs 514 A → C accounted for more than 90%. We concluded that MeltPro TB/STR represents a rapid and reliable assay for the detection of STR resistance in clinical isolates.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Evaluation; Melting curve analysis; Mycobacterium tuberculosis; Real-time PCR; Streptomycin

Mesh:

Substances:

Year:  2014        PMID: 25553930     DOI: 10.1016/j.tube.2014.12.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  5 in total

1.  Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium tuberculosis by DeepMelt Assay.

Authors:  Bin Liang; Yaoju Tan; Zi Li; Xueshan Tian; Chen Du; Hui Li; Guoli Li; Xiangyang Yao; Zhongan Wang; Ye Xu; Qingge Li
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

2.  Genotypic Distribution and a Potential Diagnostic Assay of Multidrug-Resistant Tuberculosis in Northern Thailand.

Authors:  Usanee Anukool; Ponrut Phunpae; Chayada Sitthidet Tharinjaroen; Bordin Butr-Indr; Sukanya Saikaew; Nathiprada Netirat; Sorasak Intorasoot; Vorasak Suthachai; Khajornsak Tragoolpua; Angkana Chaiprasert
Journal:  Infect Drug Resist       Date:  2020-09-30       Impact factor: 4.003

3.  GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun.

Authors:  Ming-Jin Zhang; Wen-Zhi Ren; Xue-Juan Sun; Yang Liu; Ke-Wei Liu; Zhong-Hao Ji; Wei Gao; Bao Yuan
Journal:  BMC Infect Dis       Date:  2018-05-22       Impact factor: 3.090

4.  Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China.

Authors:  Yu Pang; Haiyan Dong; Yaoju Tan; Yunfeng Deng; Xingshan Cai; Hui Jing; Hui Xia; Qiang Li; Xichao Ou; Biyi Su; Xuezheng Li; Zhiying Zhang; Junchen Li; Jiankang Zhang; Shitong Huan; Yanlin Zhao
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

5.  Accuracy of a reverse dot blot hybridization assay for simultaneous detection of the resistance of four anti-tuberculosis drugs in Mycobacterium tuberculosis isolated from China.

Authors:  Li Wan; Qian Guo; Jian-Hao Wei; Hai-Can Liu; Ma-Chao Li; Yi Jiang; Li-Li Zhao; Xiu-Qin Zhao; Zhi-Guang Liu; Kang-Lin Wan; Gui-Lian Li; Cha-Xiang Guan
Journal:  Infect Dis Poverty       Date:  2020-04-16       Impact factor: 4.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.